NCI/DCCPS Funding Opportunity Announcements for Clinical Trials

For due dates on or after January 25, 2018, NIH will require that all applications involving one or more clinical trials be submitted through a Funding Opportunity Announcement (FOA) specifically designed for clinical trials. Note that NIH supports all types of clinical trials (mechanistic, exploratory/developmental, pilot/feasibility, pragmatic, behavioral, and others), so be sure to see this page to determine if any of the human subjects research within your proposal meets the definition of a clinical trial.

The FOAs listed within this page allow clinical trials that are relevant for the scientific areas supported by NCI DCCPS. (See https://grants.nih.gov/policy/clinical-trials/specific-funding-opportunities.htm for more information on clinical trial-specific funding opportunities.). Reissued FOAs include language indicating whether clinical trials are required, meaning the proposed research must include at least one NIH-defined clinical trial, whether they are optional, meaning the proposed research may include at least one NIH-defined clinical trial, or whether they are not allowed, meaning the proposed research may not include any NIH-defined clinical trial. Please read carefully the specific language when selecting the appropriate FOA.

NCI Omnibus Announcements

Title Announcement Expiration Date Clinical Trial Optional/Required?
NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional) PAR-18-021 January 8, 2020 Optional
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)  PAR-18-290 January 8, 2020 Optional

Behavioral Research

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Cancer Prevention and Control Clinical Trials Grant Program PAR-18-559 (R01 Clinical Trial Required) January 8, 2021 Susan Czajkowski
240-276-5871
czajkows@nci.nih.gov
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) PAR-18-018 May 8, 2020 Tanya Agurs-Collins
240-276-6956
collinsta@mail.nih.gov
Optional
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical Trial Optional)  PA-18-004 January 8, 2020 Wendy Nelson
240-276-6971
nelsonw@mail.nih.gov
Optional
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)  PA-18-014 January 8, 2020 Wendy Nelson
240-276-6971
nelsonw@mail.nih.gov
Optional
Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional)  PAR-18-023 January 8, 2020 Mark Parascandola
240-276-6871
Mark.Parascandola@nih.gov
Optional
Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional) PAR-18-022 January 8, 2020 Mark Parascandola
240-276-6871
Mark.Parascandola@nih.gov
Optional
Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01 Clinical Trial Optional) PAR-18-251 June 14, 2019 Yvonne Hunt
240-276-6975
huntym@mail.nih.gov
Optional
Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21 Clinical Trial Optional)  PAR-18-250 June 14, 2019 Yvonne Hunt
240-276-6975
huntym@mail.nih.gov
Optional
Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21 Clinical Trial Optional) PAR-18-024 April 12, 2019 Rebecca Ferrer
240-276-5075
ferrerra@mail.nih.gov
Optional
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)  PAR-18-006 September 8, 2018 Frank Perna
240-276-6782
pernafm@mail.nih.gov
Optional
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)   PAR-18-016 September 8, 2018 Frank Perna
240-276-6782
pernafm@mail.nih.gov
Optional

Cancer Survivorship

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Examination of Survivorship Care Planning Efficacy and Impact (R01 Clinical Trial Optional)  PA-18-002 July 8, 2019 Janet de Moor
240-276-6806
demoorjs@mail.nih.gov
Optional
Examination of Survivorship Care Planning Efficacy and Impact (R21 Clinical Trial Optional)  PA-18-012 July 8, 2019 Janet de Moor
240-276-6806
demoorjs@mail.nih.gov
Optional

Epidemiology and Genomics Research

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) PA-18-001 May 8, 2021 Andrew N. Freedman
240-276-6697
Andrew_Freedman@nih.gov
Optional
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)  PA-18-003 July 8, 2019 Nonniekaye Shelburne
240-276-6897
nshelburne@mail.nih.gov
Optional
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional) PA-18-013 July 8, 2019 Nonniekaye Shelburne
240-276-6897
nshelburne@mail.nih.gov
Optional

Healthcare Delivery Research

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional) PA-18-492 May 8, 2021 Gurvaneet Randhawa
240-276-6940
gurvaneet.randhawa@nih.gov
Optional
Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R01 Clinical Trial Optional) PA-18-493 May 8, 2021 Gurvaneet Randhawa
240-276-6940
gurvaneet.randhawa@nih.gov
Optional
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) PAR-17-495 January 8, 2021 Erica Breslau
240-276-6773
breslaue@mail.nih.gov
Optional
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01 Clinical Trial Optional)   PA-18-005 January 8, 2020 Erica Breslau
240-276-6773
breslaue@mail.nih.gov
Optional
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21 Clinical Trial Optional)   PA-18-015 January 8, 2020 Erica Breslau
240-276-6773
breslaue@mail.nih.gov
Optional
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)  PAR-18-019 July 17, 2019 Sarah Kobrin
240-276-6931
kobrins@mail.nih.gov
Optional
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)  PAR-18-008 July 6, 2019 Sarah Kobrin
240-276-6931
kobrins@mail.nih.gov
Optional
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) PAR-18-246 April 12, 2019 Michelle Mollica
240-276-7621
mollicama@mail.nih.gov
Optional
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional) PAR-18-247 April 12, 2019 Michelle Mollica
240-276-7621
mollicama@mail.nih.gov
Optional

Health Disparities Research

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) PAR-17-496 May 15, 2020 Shobha Srinivasan
240-276-6936
ss688k@nih.gov
Optional
Research to Improve Native American Health (R21 Clinical Trials Optional) PAR-17-464 May 15, 2020 Shobha Srinivasan
240-276-6936
ss688k@nih.gov
Optional

Implementation Science

Title Announcement Expiration Date Contact Clinical Trial Optional/Required?
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)  PAR-18-007 May 8, 2020 David Chambers
240-276-5090
dchamber@mail.nih.gov

Gila Neta
240-276-6785
netagil@mail.nih.gov
Optional
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)  PAR-18-017 May 8, 2020 David Chambers
240-276-5090
dchamber@mail.nih.gov

Gila Neta
240-276-6785
netagil@mail.nih.gov
Optional